Ascendis Pharma A/S (ASND) 13F Holdings Overview (Q2 2026)

ASND ranks #9853 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

11 institutions disclose a position in ASND, but none treat it as a major bet — even Oddo Bhf Asset Management Sas, its most concentrated holder, allocates just 1.6% of its own portfolio to it.

State Street has added to its ASND position for two straight quarters, increasing it by $122.6M to reach $137.1M today.

ASND is up 2.7% today, and institutions have been net buyers of $185.8M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ASND reported a net loss of $228.0M over the trailing twelve months.

• Not yet profitable — net loss of $228.0M over the trailing twelve months
• Revenue grew 98.0% year over year
• Net income improved year over year, from -$378.1M to -$228.0M
• Current ratio of 1.04x — below the conventional 1.5x liquidity buffer
• Total liabilities currently exceed total assets (negative shareholder equity)